ARA-290 (Cibinetide) Dosage Guide: Neuropathy, Nerve Repair & Anti-Inflammation Protocol
ARA-290 (Cibinetide)
ARA-290 (Cibinetide) is a non-erythropoietic peptide derived from erythropoietin (EPO), studied for its anti-inflammatory, neuroprotective, and tissue-repair effects without stimulating red blood cell production.
How It Works
Innate Repair Receptor (IRR) Activation → Inflammation ↓ + Nerve Repair ↑ + Tissue Protection ↑
ARA-290 selectively activates the innate repair receptor (IRR), a pathway involved in reducing inflammation, protecting nerve tissue, and promoting cellular repair. Unlike EPO, it does not stimulate hematocrit or red blood cell production.
ARA-290 is derived from erythropoietin, but it is non-erythropoietic.
It is studied for nerve repair, inflammation control, and tissue protection.
Unlike EPO, it does not stimulate red blood cell production or raise hematocrit.
It is often discussed in small fiber neuropathy and nerve-related research contexts.
ARA-290 Protocol
10 mg vial + 1.0 mL BAC Water → 1 unit = 100 mcg → Daily Nerve + Repair Support
Standard Setup
Vial
10 mg
Water
1.0 mL bacteriostatic water
Concentration
10 mg/mL
Conversion
1 unit = 100 mcg
Weeks 1–4
Starting Phase
Dose2 mg daily
Units20 units
Volume0.20 mL
Weeks 5–8
Build Phase
Dose2–4 mg daily
Units20–40 units
Volume0.20–0.40 mL
Protocol Details
FrequencyOnce daily
TimingMorning or early afternoon
RouteSubcutaneous
Cycle Length4–8 weeks
Simple structure
ARA-290 is usually discussed as a daily nerve-repair and inflammation-support peptide. Consistency matters because the goal is not an immediate stimulant effect — it is steady repair signaling over time.
ARA-290 is usually discussed as a daily nerve-repair and inflammation-support peptide. Consistency matters because the goal is not an immediate stimulant effect — it is steady repair signaling over time.
Neuropathy Protocol (Targeted Use)
Targeted Nerve Support → Consistent Daily Dosing → 6–8 Week Repair Window
Weeks 1–4
Targeted Start
Dose4 mg daily
Units40 units
Volume0.40 mL
Weeks 5–8
Targeted Support
Dose4 mg daily
Units40 units
Volume0.40 mL
Protocol Details
FrequencyOnce daily
TimingMorning preferred
RouteSubcutaneous
Cycle Length6–8 weeks
Targeted Use Notes
Designed for nerve-related conditions such as small fiber neuropathy
Consistent daily dosing is key for nerve repair signaling
Often requires full 6–8 week cycles for noticeable effects
Can be paired with supportive recovery protocols
When & Where to Inject
Subcutaneous injection preferred
Common sites: abdomen, thigh, upper arm
Rotate injection sites daily
Use a consistent time each day
Best Time to Use
Morning is commonly preferred for consistent daily use.
Early afternoon may also work if morning timing is not practical.
Using it at the same time each day makes symptom tracking easier.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water1.0 mL
Concentration10 mg/mL
Conversion1 unit = 100 mcg
Dose Reference
10 units = 1 mg
20 units = 2 mg
40 units = 4 mg
Reconstitution Steps
Draw 1.0 mL bacteriostatic water
Inject slowly into vial
Gently swirl, do not shake
Allow full dissolution
Label with the reconstitution date
Refrigerate after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed)
Refrigerated (2–8°C): ~12–24 months
Frozen (−20°C): up to ~2–3 years
Store sealed, dry, and protected from light
Reconstituted (Mixed)
Refrigerate at 2–8°C after reconstitution
Do not freeze after mixing
Use within 30 days
Avoid repeated temperature changes
Best Practice
Keep the vial refrigerated, protected from light, and avoid unnecessary handling. If the solution becomes cloudy, discolored, or develops visible particles, it is safer not to continue using it.
Keep the vial refrigerated, protected from light, and avoid unnecessary handling. If the solution becomes cloudy, discolored, or develops visible particles, it is safer not to continue using it.
Cycle Length & Time Between Cycles
Daily Repair Phase → Reassess Symptoms → Break or Repeat if Needed
Standard Cycle Structure
General Cycle4–8 weeks
Neuropathy Cycle6–8 weeks
Time Off2–4 weeks before reassessing
Why cycle?
ARA-290 is typically discussed in defined repair-support windows. Taking time off after a cycle helps evaluate whether nerve symptoms, sensation, inflammation, or recovery markers improved before repeating another phase.
ARA-290 is typically discussed in defined repair-support windows. Taking time off after a cycle helps evaluate whether nerve symptoms, sensation, inflammation, or recovery markers improved before repeating another phase.
When to Take a Break Sooner
No noticeable improvement after a full support window
Injection site irritation becomes persistent
Fatigue, headache, or unexpected symptoms appear
You are continuing without a clear nerve, inflammation, or recovery goal
Monitoring During Use
Nerve pain or neuropathy symptoms
Inflammation and recovery markers
Sensation improvements
General recovery and function
Benefits
Supports nerve repair and regeneration
Reduces inflammation
Studied in small fiber neuropathy
May improve tissue recovery and healing
Non-erythropoietic, does not raise hematocrit
Potential Side Effects
Mild injection site irritation
Rare headache or fatigue
Generally well tolerated in studies
Important Notes
Does not affect red blood cell production like EPO
Often discussed for neuropathy and nerve-related conditions
Works best with consistent daily use
Research is still emerging
ARA-290 is usually framed around repair signaling, not performance enhancement
Important Disclaimer
ARA-290 (Cibinetide) is an investigational peptide and is not FDA-approved. This content is for educational and research purposes only.
Comments
Post a Comment